Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029009 | 0.87 | GPR84 (0.49) | GPR84ATMMEN1KMT2AMAPT | |
| SCHEMBL18923935 | 0.86 | GPR84 (0.46) | GPR84ATMMEN1KMT2AMAPT | |
| SCHEMBL30969153 | 0.86 | GPR84 (0.46) | GPR84ATMMEN1KMT2AMAPT | |
| SCHEMBL19059561 | 0.85 | GPR84 (0.47) | GPR84ATMMEN1KMT2AMAPT | |
| SCHEMBL273916 | 0.84 | HTR2A (0.47) | GPR84ATMMEN1KMT2AMAPT | |
| SCHEMBL29611302 | 0.84 | HTR2A (0.47) | GPR84ATMMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL30098563 | 0.82 | PMP22 (0.49) | GPR84ATMMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL4526379 | 0.82 | PMP22 (0.49) | GPR84ATMMEN1KMT2AMAPT | |
| SCHEMBL28981236 | 0.80 | MAPT (0.45) | GPR84ATMMEN1KMT2AMAPT | |
| SCHEMBL13335152 | 0.80 | ATM (0.54) | GPR84ATMMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025903-A1 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | ATHIRA PHARMA, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TONGJI UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-12-09 | — | — | US | disclosed |
| US-10954273-B2 | Hybrid cyclic libraries and screens thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190389911-A1 | HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-12-26 | — | — | US | disclosed |
| US-10351572-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | Magenta Therapeutics Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9889213-B2 | Multimodal imaging of fibrin | THE GENERAL HOSPITAL CORPORATION (US) | 2018-02-13 | — | — | US | disclosed |
| US-8778305-B2 | PSMA-binding agents and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TNNI3, TNNT2, MKI67 | GPR84 3130/4885ATM 4740/4885MEN1 3479/4885 |
| US-10954273-B2 | Hybrid cyclic libraries and screens thereof | CACYBP, HSPBP1, PEBP1 | GPR84 3317/4885ATM 4313/4885MEN1 2998/4885 |
| US-20190389911-A1 | HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF | CACYBP, HSPBP1, PEBP1 | GPR84 3317/4885ATM 4313/4885MEN1 2998/4885 |
| US-20240025903-A1 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | HDGF, HGF, BDNF | GPR84 1288/4885ATM 3246/4885MEN1 2140/4885 |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | GPR84 1879/4885ATM 338/4885MEN1 3601/4885 |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | GPR84 1302/4885ATM 3258/4885MEN1 213/4885 |
| US-10351572-B2 | Aryl hydrocarbon receptor antagonists and uses thereof | AHR, ARNT, AIPL1 | GPR84 44/4885ATM 3797/4885MEN1 4784/4885 |
| US-20210379033-A1 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | AHR, ARNT, NCOR1 | GPR84 36/4885ATM 3112/4885MEN1 4680/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GPR84 1294/4885ATM 194/4885MEN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.